833 reports of this reaction
6.3% of all GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE reports
#2 most reported adverse reaction
DIZZINESS is the #2 most commonly reported adverse reaction for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, manufactured by RB Health (US) LLC. There are 833 FDA adverse event reports linking GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE to DIZZINESS. This represents approximately 6.3% of all 13,133 adverse event reports for this drug.
Patients taking GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 833 FDA reports for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 6.3% of all adverse event reports for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, making it one of the most commonly reported side effect.
If you experience dizziness while taking GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.